Marcus Lefebure, PhD

BeOne Medicines Ltd, United Kingdom

Poster(s):

• 1421 - Safety and Efficacy of Zanubrutinib in a Subgroup of Older Patients (≥75 Years) With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma From the SEQUOIA Study

• 1426 - Efficacy and Safety of Zanubrutinib in a Fit Subgroup of Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Post Hoc Analyses from the SEQUOIA Study